BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
前收盘价
US$0.33
−US$0.107 · -24.49%
盘中时间采用ET。市场数据可能有所延迟。
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
日内区间
当前US$0.33
52周区间
当前US$0.33
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | — | 135.1万 USD | 135.1万 USD |
| 销货成本 | 8.7万 USD | — | 30.2万 USD | — | — |
| 毛利 | −8.7万 USD | — | −30.2万 USD | 135.1万 USD | 135.1万 USD |
| 研究与开发 | 438.8万 USD | 264.4万 USD | 727.2万 USD | 2558.2万 USD | 3688.8万 USD |
| 销售、一般及管理费用 | 455.7万 USD | 611万 USD | 750.7万 USD | 1300.8万 USD | 3070.3万 USD |
| 营业费用 | 885.8万 USD | 875.4万 USD | 1477.9万 USD | 3859万 USD | 6759.1万 USD |
| 利息收入 | 7.8万 USD | 5.9万 USD | 42.1万 USD | 19.5万 USD | 9.8万 USD |
| 利息支出 | — | — | — | 1.7万 USD | 8.7万 USD |
| 折旧和摊销 | 8.7万 USD | 28.5万 USD | 30.2万 USD | 23.2万 USD | 6.1万 USD |
| 营业利润 | −894.5万 USD | −875.4万 USD | −1508.1万 USD | −3723.9万 USD | −6624万 USD |
| 净利润 | −799.2万 USD | −1112.3万 USD | −2102.6万 USD | −3327.9万 USD | −6417.9万 USD |
公司数据更新于 2026年11月22日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。